SEEBRI NEOHALER
LOE ApproachingNDAINHALATIONPOWDER
Approved
Oct 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEEBRI NEOHALER is an inhaled powder formulation of an unknown active pharmaceutical ingredient approved by the FDA in October 2015. The specific indication and mechanism of action are not disclosed in available data, but the inhalation route suggests pulmonary or respiratory application. This small-molecule product represents a Novartis respiratory portfolio asset.
LOE Approaching2.0 years to LOE
Product faces imminent loss of exclusivity with declining revenue trajectory; brand team likely focused on transition planning and generic preparation rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Worked on SEEBRI NEOHALER at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.